The Potential Role of sPD-L1 as a Predictive Biomarker in EGFR-Positive Non-Small-Cell Lung Cancer by Vesna Ćeriman Krstić, Dragana Jovanović, Natalija Samardžić, Milija Gajić, Jelena Kotur Stevuljević, Aleksandra Klisic, Ivan Soldatović, Damir Radončić, Marina Roksandić Milenković, Biljana Šeha, Nikola Čolić, Katarina Lukić, Milan Savić

Subjects: Get full text

Increased serum soluble PD-l1 levels in patients with advanced stages of chronic kidney disease by Ayaka Hayashi, Ayaka Hayashi, Hiroto Ishihara, Mayuko Kawabe, Kazuhiko Kato, Kazuhiko Kato, Akio Nakashima, Akio Nakashima, Izumi Yamamoto, Teppei Sakano, Teppei Sakano, Hiroe Kobashi, Makoto Morita, Makoto Morita, Takashi Yokoo, Mitsuyoshi Urashima

Subjects: Get full text

Germline Human Leukocyte Antigen Status is Associated With Immunotherapy-Induced Pneumonitis and Treatment Response in Patients With Non–Small Cell Lung Cancer With High Programmed... by Alvin H.K. Cheung, MBBS, PhD, Zeta Mui, MPhil, Walter W. Yeung, PhD, Chit Chow, PhD, Mandy F. Yu, BSc, Olivia H. Chen, MD, PhD, Kit-Yee Wong, MPhil, Fuda Xie, MPhil, Yat Ming Lau, MBBS, Alfred S-L. Cheng, PhD, Wei Kang, PhD, Ka-Fai To, MBChB, Tony S. Mok, MD, Molly S.C. Li, MBBS

Subjects: Get full text

Prognostic and clinicopathological role of soluble programmed cell death ligand-1 in patients with diffuse large B-cell lymphoma: a meta-analysis by Hongbin Lu, Lulu Luo, Jie Mi, Min Sun, Huaping Wang, Zheng Wang, Wenwen Ding

Subjects: “…PD-L1…”
Get full text

Sigma1 inhibitor suppression of adaptive immune resistance mechanisms mediated by cancer cell derived extracellular vesicles by Paola A. Castagnino, Derick A. Haas, Luca Musante, Nathalia A. Tancler, Bach V. Tran, Rhonda Kean, Alexandra R. Steck, Luis A. Martinez, Elahe A. Mostaghel, D. Craig Hooper, Felix J. Kim

Subjects: Get full text

Targeted Delivery of BMS-1166 for Enhanced Breast Cancer Immunotherapy by Yu Z, Zhou Z, Zhao Y

Subjects: “…pd-l1…”
Get full text

Insights into the mechanisms of serplulimab: a distinctive anti-PD-1 monoclonal antibody, in combination with a TIGIT or LAG3 inhibitor in preclinical tumor immunotherapy studies by Yizhou Zhang, Ruicheng Wei, Ge Song, Xinyi Yang, Mengli Zhang, Wei Liu, Aiying Xiong, Xuehan Zhang, Qianhao Li, Wan-Jen Yang, Chencheng Han, Rui Liu, Chen Hu, Qingyu Wang, Jun Zhu, Yongqiang Shan

Subjects: “…Anti-PD-1/PD-L1…”
Get full text

Disulfidptosis as a key regulator of glioblastoma progression and immune cell impairment by Yifu Shu, Jing Li

Subjects: Get full text

Prognostic implications of immune classification based on PD-L1 expression and tumor-infiltrating lymphocytes in endocervical adenocarcinoma by Li-Jun Wei, Zi-Yun Wu, Li-Yan Wu, Ying-Wen Wu, Hao-Yu Liang, Rong-Zhen Luo, Li-Li Liu

Subjects: “…PD-L1…”
Get full text

ArfGAP with the SH3 Domain, Ankyrin Repeat and PH Domain 1 Inversely Regulates Programmed Death-Ligand 1 Through Negative Feedback of Phosphorylated Epithelial Growth Factor Recept... by Chiba N, Menju T, Shimazu Y, Toyazaki T, Sumitomo R, Miyamoto H, Tamari S, Nishikawa S, Date H

Subjects: Get full text

PD-L1 positive platelets mediate resistance to immune checkpoint inhibitors in patients with colorectal cancer by Jiacheng Li, Jia Liu, Shifeng Yang, Yu Xia, Qingzhe Meng, Biying Sun, Yansong Liu, Bin Zhao, Jiaqi Jin, Hui Xu, Lihong Wang, Pengxia Zhang, Zhuoxin Cheng

Subjects: “…PD-L1…”
Get full text

A Smart Nanomedicine Unleashes a Dual Assault of Glucose Starvation and Cuproptosis to Supercharge αPD‐L1 Therapy by Yiming Xu, Yuan Wu, Xinjie Zheng, Dongxue Wang, Hangqi Ni, Weiyu Chen, Kai Wang

Subjects: Get full text

Differentiation status determines the effects of IFNγ on the expression of PD-L1 and immunomodulatory genes in melanoma by Teitur Sævarsson, Adrián López García de Lomana, Ólafur Sánchez, Veerle van Esch, Gunnar Bjarni Ragnarsson, Siggeir Fannar Brynjólfsson, Eiríkur Steingrímsson, Berglind Ósk Einarsdóttir

Subjects: Get full text

Toxic epidermal necrolysis induced by nivolumab therapy for unresectable intraperitoneal cancer by Hiroyoshi Nozaki, Jiro Uehara, Naoki Kato, Masaru Honma, Akemi Ishida-Yamamoto

Subjects: Get full text

Platinum drugs upregulate CXCR4 and PD‐L1 expression via ROS‐dependent pathways, with implications for novel combined treatment in gastric cancer by Xiaoyu Kang, Lin Zhang, Shushang Liu, Fei Wang, Haiming Liu, Fenli Zhou, Fei Wu, Haohao Zhang, Daiming Fan, Yongzhan Nie, Zhangqian Chen

Subjects: Get full text

DRG2 as a Biomarker to Enhance the Predictive Efficacy of PD-L1 Immunohistochemistry Assays by Muralidharan Mani, Seong Hee Choi, Hyuk Nam Kwon, Jeong Woo Park

Subjects: Get full text

Enhanced effect of radiofrequency ablation on HCC by siRNA-PD-L1-endostatin Co-expression plasmid delivered by Pengfei Chen, Kun Li, Jinwei Chen, He Hei, Jiaxin Geng, Nannan Huang, Mengyu Lei, Huijie Jia, Jianzhuang Ren, Chenwang Jin

Subjects: Get full text

Clinical characteristics, diagnosis, treatment, and prognosis of Atezolizumab-induced encephalitis, aseptic meningitis or meningoencephalitis by Qingzi Yan, Yixiang Hu, Xiang Liu, Hong Xia

Subjects: Get full text

Neoadjuvant chemoradiotherapy up-regulates PD-L1 in radioresistant colorectal cancer by Sung Uk Bae, Hye Won Lee, Jee Young Park, Incheol Seo, Jae-Min Cho, Jin Young Kim, Ju Yup Lee, Yoo Jin Lee, Seong Kyu Baek, Nam Kyu Kim, Sang Jun Byun, Shin Kim

Subjects: Get full text

Discovery of novel biphenyl compounds bearing hydroxamic acid moiety as the first PD-L1/class I HDACs dual inhibitors by Dandan Yuan, Yali Gao, Lin Xia, Han Liu, Xingye Wu, Xueyan Ding, Yudan Huang, Changchun Deng, Jin Li, Wenqi Dai, Jieqing Liu, Junjie Ma

Subjects: “…PD-1/PD-L1…”
Get full text